Loading...
•
Dec 31, 2021
Evofem Biosciences Q4 2021 Earnings Report
Evofem Biosciences experienced strong growth, with net product sales more than doubling in Q4 2021 and net cash burn decreasing.
Key Takeaways
Evofem Biosciences reported a strong fourth quarter, driven by a 109% increase in net product sales compared to the previous quarter. The company also reduced its net cash burn rate and completed enrollment in a Phase 3 trial for Phexxi.
Net product sales increased 109% to $3.6 million in the fourth quarter of 2021.
Net cash burn rate decreased to $16.8 million in the fourth quarter of 2021.
Enrollment completed in Phase 3 trial of Phexxi for prevention of chlamydia and gonorrhea in women.
Secured a $50 million equity line of credit.
Revenue by Segment
Forward Guidance
Evofem Biosciences is focused on the ongoing development of Phexxi and future growth of sales of Phexxi and the Company generally.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...